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We recently identified T cell epitopes associated with human allergic responses. In a majority of cases, responses
focused on a few immunodominant epitopes which can be predicted on the basis of MHC binding characteristics.
Several observations from our studies challenged the assumption that T cell epitopes are derived from the same
allergen proteins that bind IgE. Transcriptomic and proteomics analysis identified pollen proteins, not bound by
IgE. These novel Timothy Grass proteins elicited vigorous Th2 responses, suggesting that unlinked T cell help is
operational in pollen-specific responses. Thus, the repertoire of antigens recognized by T cells is much broader
than IgE-binding allergens. Additionally, we evaluated the use of epitopes from these novel antigens to assess
immunological changes associated with Specific Immunotherapy (SIT). We found that a marked decrease in IL5
production is associated with clinically efficacious SIT, suggesting that these novel antigens are potential
immunomarkers for SIT efficacy.
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Herein we will briefly summarize data generated in our
laboratory pertaining to the identification of T cell epi-
topes associated with allergic responses in humans. We
will further discuss this data in the context of the poten-
tial use of allergen-derived T cell epitopes as biomarkers
of specific immunotherapy (SIT).
These studies were prompted by the observation that
T cells contribute to pathology associated with allergy
both directly and indirectly through modulation of im-
mune responses [1]. The involvement of T cells in SIT has
been reviewed recently [2-4], and it has been suggested
that epitopes may provide a tool to monitor disease and
therapeutic intervention. Furthermore, several studies
have forwarded the hypothesis that T cell epitopes them-
selves have potential as immunotherapeutic vaccine com-
ponents [5,6]. Yet, for the majority of the most common
allergens, the corresponding T cell epitopes have not been
thoroughly mapped.* Correspondence: alex@lji.org
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unless otherwise stated.Our approach and results will be articulated in three
main steps. First, we will review the development of tech-
niques and general approaches for the identification of
allergen-derived epitopes and their application to some of
the most common allergen sources. Second, we will
describe a series of studies that questioned the assumption
that T cell epitopes are derived from the same allergen
proteins that bind IgE. The final series of experiments
described here will relate to the use of epitopes to assess
immunological changes associated with SIT maintenance
phase.A general strategy for epitope identification and
characterization
A number of different methods are available for the iden-
tification and characterization of peptide epitopes recog-
nized by human class II restricted T cells. They include
generation of stable T cell lines and clones, isolation of
naturally processed ligands, screening of libraries of over-
lapping peptides, and generation of mimotope libraries
and prediction of HLA class II binding capacity by bio-
informatics analysis.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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of bioinformatics predictions combined with experimen-
tal tests of predicted binders using lymphocytes derived
from allergic patients [7-10]. One issue that has to be
considered in the implementation of this approach is the
fact that HLA class II molecules are very heterogeneous.
They are in fact encoded by four different loci (HLA
polygeny), and at each of these loci hundreds of allelic
variants are represented in the general population (HLA
polymorphism) [11-14].
To address this challenge, we put forth the hypothesis
that while the large number of HLA class II variants
would likely be reflected in a large degree of heterogen-
eity of responses, a large fraction of the response might
be accounted for by a limited number of more dominant
epitopes. We further hypothesized that T cell epitopes
capable of cross-binding multiple HLA class II molecules
(i.e., promiscuous epitopes) would likely be amongst such
dominant epitopes. Hence, we suggest that predicting pro-
miscuous HLA class II epitopes might offer a practical
means to identify a rather significant fraction of T cell al-
lergen epitope specificities.Validation of the approach
The potential merit of the hypothesis formulated above
was tested experimentally in the Timothy Grass (TG)
system [10]. For these studies, we considered all TG pro-
teins considered allergens by IUIS (Phl p 1, 2, 3, 4, 5, 6,
7, 11, 12, 13). It is important to note that these allergens
were previously defined based on their capacity to elicit
IgE reactivity. To ensure we would comprehensively de-
tect T cell responses directed against these allergens, a
series of 687 15-mer peptides overlapping by 10 residues
were synthesized to completely span each protein se-
quence. Peptide pools were tested by ELISPOT for reactiv-
ity using short-term T cell lines obtained by in vitro
restimulation with TG extract. Positive pools were subse-
quently deconvoluted to identify the individual 15-mer(s)
eliciting allergen-specific responses.
Upon completion of the screen that included 10 non-
allergic donors and 33 allergic donors, 8 of which were in
maintenance phase of SIT, we noted, as expected, a large
degree of heterogeneity of responses. At least 43 different
epitopes/antigenic regions were defined. However, we also
noted that a few regions accounted for a disproportion-
ately large fraction of the responses. In fact, just the top
nine regions accounted for over half of the total response.
Subsequent analysis verified that these epitopes were in-
deed promiscuous (i.e., they were capable of eliciting re-
sponses in the context of multiple HLA). Further analysis
also revealed that binding predictions could identify the
most promiscuous epitopes accounting for a relatively
large fraction of the responses.Based on these results, we developed a predictive strat-
egy to identify specifically those peptides binding to
multiple HLA. We applied this strategy to a larger scale
effort targeting epitope identification for an additional
set of 28 allergen sources [7,9,15]. These included cock-
roach antigens and various tree, grass, fungi, and animal
allergens. Our selection of these sources was based on a
focus towards allergens that were relatively common at
the two clinical sites participating in the study and for
which allergen sequences were available from IUIS. The
predictive strategy validated in the TG model system
was utilized and a total of over 250 different antigenic
regions were identified. To the best of our knowledge,
this study reported the first-ever human T cell epitopes
from 16 of these common allergen sources.
In conclusion, our studies have found that in a majority
of cases allergen-specific responses are directed against
relatively few immunodominant epitopes. Further, these
epitopes can be identified and/or predicted on the basis of
MHC binding characteristics.
Are T cell epitopes derived from the same allergen
proteins that bind IgE?
It was generally assumed that T cell epitopes are derived
from the same allergens that bind and elicit IgE responses.
However, in the course of the studies described above, we
made two observations that led us to question the validity
of this assumption.
First, in both the TG and cockroach allergy systems,
we observed that T cell responses and IgE responses did
not correlate at the level of individual patients [9,10].
More specifically, while in general the magnitude of T
cell responses and IgE titers directed against allergen ex-
tracts were positively correlated, a different picture was
noted in the case of individual recombinant allergens.
That is, in several patients, a vigorous IgE response might
be detected against antigens for which no T cell response
was detected while, conversely, in the same patient the
dominant T cell response was detected against a different
antigen not dominantly targeted by IgE.
Second, in several patients, no T cell response could
be detected against any of the known IgE-binding aller-
gens, despite vigorous T cell responses to the TG extract.
We hypothesized that these observations might be ex-
plained by T cell responses targeting additional pollen
proteins other than the known allergens. The absence of
an exact correlation of T and B cell responses on the
antigen level is not really surprising. In fact, this notion,
called “antigen bridge” [16-21], while not experimentally
explored in the case of allergen specific responses, is
“textbook immunology” when, for example, infectious
diseases are considered. In this case, it is well appreci-
ated that helper T cells specific for internal proteins of
common viruses (influenza, hepatitis B) provide effective
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virus surface.Transcriptomic and proteomic analysis of TG to test the
breadth of the TG epitope repertoire
Based on these data, we hypothesized that Th2 responses
in allergic patients might recognize antigens contained in
the pollen particles but not necessarily limited to the ones
bound by IgE. Testing this hypothesis required a multidis-
ciplinary approach (Figure 1), including a transcriptomic
analysis based on obtaining mRNA sequences from TG
pollen. This analysis was coupled with a proteomics ana-
lysis, which identified pollen proteins by mass spectrom-
etry (MS) from extract using the transcriptome as a
reference. Together, these two analyses enabled the immu-
nomics analysis in which peptides binding promiscuously
to HLA class II molecules were predicted, synthesized and
tested for T cell recognition.Figure 1 Scheme of epitope identification process. Diagrammatic repre
identification as detailed in this review.Identification of novel proteins was accomplished by
isolating TG pollen mRNA and analyzing high-throughput
sequencing from an Illumina Genome Analyzer. A total of
1,016,285 unique, putative transcripts (including allelic var-
iants and isoforms) were identified. Next, we used gel sep-
aration and MS analysis to identify which of the newly
identified transcripts encoded proteins detectable in TG
pollen. More specifically, pollen extract was separated on
2D gels and specific spots were picked for further analysis
based on antibody or protein staining. These spots were
then cut out from the gel and analyzed by mass spectrom-
etry. As a result, 83 new proteins derived from the 2D gel
and an additional ten proteins derived from whole extract
MS analysis were chosen for further studies [8].
To identify T cell epitopes on the basis of HLA class II
binding predictions, we predicted the capacity of pep-
tides derived from the novel proteins to bind a panel of
25 common HLA class II DR, DP, and DQ molecules
selected to represent the most prevalent alleles in thesentation of the process of antigen, epitope, and biomarker
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ethnicities [12]. A set of 822 peptides predicted promis-
cuous binders (i.e., >12 HLA variants predicted to be
bound) was then synthesized and tested for IL5 produc-
tion in PBMC from TG allergic donors.
When compared to known allergens, the results clearly
indicated that a majority of Th2 responses in TG allergic
individuals target epitopes derived from novel antigens,
some of which are not targeted by IgE responses. Further
experiments confirmed this discovery by showing that
memory T cells are the source of IL5 T cell responses after
in vitro expansion, and showing that responses to both
conventional and novel TG antigens can be detected dir-
ectly ex vivo.
In conclusion, the results summarized in this section
indicate that novel TG proteins elicited Th2 responses,
explaining the reactivity gap between known allergens
and whole extract. IL5 production was directed to sev-
eral antigens not targeted by IgE or IgG, suggesting that
unlinked T-cell help is operational in pollen-specific re-
sponses. In the end, the universe of T cell inducing anti-
gens was found to be much broader than that delineated
by IgE-binding allergens.
Immunological changes associated with SIT maintenance
phase
Despite unquestionable evidence demonstrating that SIT
is effective in treating allergic disease [22-25], several
limitations are also associated with this treatment modal-
ity. Safety considerations dictate a rather laborious regi-
men of administration. The same considerations limit the
dosing, potentially also limiting the effectiveness of the
treatment. Various alternative treatment modalities are be-
ing considered, but their design and testing has been ham-
pered by an incomplete understanding of mechanisms of
action and by the lack of immunomarkers of efficacy
[26,27]. These limitations in turn have slowed the process
of design and testing of alternatives, potentially inhibiting
the development of improved immunotherapies.
With these considerations in mind, we initiated a com-
parison of cytokine production in allergic and SIT do-
nors [28]. In these comparisons, we utilized both known
and novel TG antigens. Epitope specific responses were
analyzed in a cross-sectional study utilizing ELISPOT as-
says specific for IL5, IL10, IFN-gamma and IL17. The re-
sults of these experiments revealed, for both known and
novel allergens/antigens, a marked decrease in IL5 and
no difference in IL10 production for the SIT donors.
The decrease in IL5 was expected, as this was chosen as
representative of Th2 cytokines. Conversely, the lack of
effect in terms of IL10 was somewhat unexpected in
light of previous observations [29,30], and might be re-
lated to the fact that IL10 production has been reported
to be an early and transient event associated with earlySIT phases (unlike the maintenance phase associated with
the SIT donors analyzed here).
When epitopes from known and novel antigens were
compared, the decrease in IL5 production associated with
SIT was similar, and, if anything, more pronounced in the
case of the novel antigens and epitopes. Taken together,
these data have suggested several potential immunomar-
kers for SIT efficacy as well as possible approaches to-
wards defining a mechanism of action.
A subset of NTGAs for which IL5 responses are most
down-regulated in SIT
Based on these results, we selected a subset of novel
Timothy Grass antigens (NTGAs) and epitopes for which
the IL-5 response was found to be particularly down-
modulated in SIT and used it for additional studies in new
donors [28]. An important consideration with respect to
the relevance of these antigens and epitopes for their
potential use in therapeutic applications is that several of
them are not targeted by IgE, and are thus expected to
offer a safer alternative for immunotherapy. When these
epitopes were tested in a new donor cohort of SIT and al-
lergic controls, the drastic decrease in IL5 production was
replicated. Concomitantly, a highly significant increase in
IFN-gamma production was noted for these selected epi-
topes when SIT donors were compared to untreated aller-
gic patient controls. The lack of change in the levels of
IL10 production noted in the previous cohort was also
reproduced. Finally, additional experiments demonstrated
that the reduction of Th2 responses in SIT donors is not
limited to IL5, but also extends to other Th2 cytokines
such as IL4 and IL13.
Modulation of cytokine responses to the MNA pool
correlates with SIT efficacy
In the course of recruitment of the SIT donors utilized
in these experiments, each donor provided a subjective
evaluation as to whether or not the treatment had helped
to alleviate their symptoms. When the data pertaining to
the modulation of the IL5 response was subsequently ana-
lyzed, it was found that modulation of IL5 responses were
much more pronounced in the donors self-reporting
benefit from treatment [28]. That is, IL5 responses in the
group of individuals that did not benefit from SIT were es-
sentially indistinguishable from those of allergic untreated
donors, while the responses seen in the group of SIT do-
nors that subjectively reported to have benefitted from
treatment were significantly lower.
These data raise the possibility that T cell responses to
certain modulated novel antigen (MNA) epitopes can be
used as biomarkers of SIT efficacy. However, additional
studies are clearly required, including those addressing
larger patient cohorts as well as longitudinal studies (e.g.,
samples from the same patient during the course of SIT
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tions of SIT clinical efficacy. These subsequent studies
should also evaluate whether modulation of Th2 re-
sponses to specific epitopes follows or precedes the clin-
ical benefit, and determine how long the modulation
lasts. These studies should also correlate changes in
epitope specific responses with other immunological
changes that have been proposed as biomarkers of SIT
efficacy, such as increases in IgG4 titers.
Synopsis
We utilized a bioinformatics-based approach to charac-
terize T cell responses to common allergens. Peptides
from novel, non-IgE-binding proteins elicited Th2 re-
sponses, suggesting that unlinked T-cell help is oper-
ational in pollen-specific responses. Thus, the repertoire
of T cell allergens is much broader than that defined by
IgE-binding. IL5 responses to these novel antigens from
SIT donors that subjectively reported to have benefitted
from treatment were significantly lower than those of in-
dividuals that did not benefit from SIT. These observa-
tions raise the possibility that allergen specific epitopes
can be used as biomarkers of SIT efficacy.
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